HCMV Activates the IL-6-JAK-STAT3 Axis in HepG2 Cells and Primary Human Hepatocytes

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Lepiller, Quentin ^a,b   Abbas, Wasim ^a   Kumar, Amit ^a   Tripathy, Manoj K ^a   Herbein, Georges ^a  

^a CHU Besançon ^*  (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN 1; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; KI 67 ANTIGEN; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PROTEIN P72; STAT3 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL TRANSFORMATION; COLONY FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; LIVER CARCINOGENESIS; MOLECULAR DYNAMICS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; VIRUS ACTIVATION; VIRUS ENTRY; WESTERN BLOTTING;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOMEGALOVIRUS; ENZYME ACTIVATION; HEP G2 CELLS; HEPATOCYTES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-6; JANUS KINASES; LIVER NEOPLASMS; MICE; STAT3 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

HUMAN HERPESVIRUS 5;

EID: 84875440552     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059591     Document Type: Article

References (62)

1. Aravalli RN, Steer CJ, Cressman EN, (2008) Molecular mechanisms of hepatocellular carcinoma. Hepatology 48: 2047-2063.
2. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, et al. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317: 121-124.
3. Park EJ, Lee JH, Yu GY, He G, Ali SR, et al. (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140: 197-208.
4. Nakagawa H, Maeda S, Yoshida H, Tateishi R, Masuzaki R, et al. (2009) Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer 125: 2264-2269.
5. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, et al. (2009) High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 124: 2766-2770.
6. Kishimoto T, (2005) Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23: 1-21.
7. Lepiller Q, Tripathy MK, Di Martino V, Kantelip B, Herbein G, (2011) Increased HCMV seroprevalence in patients with hepatocellular carcinoma. Virol J 8: 485.
8. He G, Karin M, (2011) NF-kappaB and STAT3- key players in liver inflammation and cancer. Cell Res 21: 159-168.
9. Yu H, Pardoll D, Jove R, (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809.
10. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, et al. (2009) Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci 1171: 59-76.
11. Coaquette A, Bourgeois A, Dirand C, Varin A, Chen W, et al. (2004) Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients. Clin Infect Dis 39: 155-161.
12. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, et al. (2002) Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62: 3347-3350.
13. Harkins L, Volk AL, Samanta M, Mikolaenko I, Britt WJ, et al. (2002) Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 360: 1557-1563.
14. Harkins LE, Matlaf LA, Soroceanu L, Klemm K, Britt WJ, et al. (2010) Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae 1: 8.
15. Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS, (2003) High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 170: 998-1002.
16. Zafiropoulos A, Tsentelierou E, Billiri K, Spandidos DA, (2003) Human herpes viruses in non-melanoma skin cancers. Cancer Lett 198: 77-81.
17. Baryawno N, Rahbar A, Wolmer-Solberg N, Taher C, Odeberg J, et al. (2011) Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest 121: 4043-4055.
18. Melnick M, Sedghizadeh PP, Allen CM, Jaskoll T, (2012) Human cytomegalovirus and mucoepidermoid carcinoma of salivary glands: cell-specific localization of active viral and oncogenic signaling proteins is confirmatory of a causal relationship. Exp Mol Pathol 92: 118-125.
19. Soroceanu L, Cobbs CS, (2010) Is HCMV a tumor promoter? Virus Res 157: 193-203.
20. Lepiller Q, Aziz Khan K, Di Martino V, Herbein G, (2011) Cytomegalovirus and tumors: two players for one goal-immune escape. Open Virol J 5: 60-69.
21. Khan KA, Coaquette A, Davrinche C, Herbein G, (2009) Bcl-3-regulated transcription from major immediate-early promoter of human cytomegalovirus in monocyte-derived macrophages. J Immunol 182: 7784-7794.
22. Murphy E, Yu D, Grimwood J, Schmutz J, Dickson M, et al. (2003) Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci U S A 100: 14976-14981.
23. Carlier J, Martin H, Mariame B, Rauwel B, Mengelle C, et al. (2011) Paracrine inhibition of GM-CSF signaling by human cytomegalovirus in monocytes differentiating to dendritic cells. Blood 118: 6783-6792.
24. Landberg G, Tan EM, Roos G, (1990) Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: a new view of the cell cycle. Exp Cell Res 187: 111-118.
25. Carlquist JF, Edelman L, Bennion DW, Anderson JL, (1999) Cytomegalovirus induction of interleukin-6 in lung fibroblasts occurs independently of active infection and involves a G protein and the transcription factor, NF-kappaB. J Infect Dis 179: 1094-1100.
26. Iwamoto GK, Konicek SA, (1997) Cytomegalovirus immediate early genes upregulate interleukin-6 gene expression. J Investig Med 45: 175-182.
27. Boldogh I, AbuBakar S, Millinoff D, Deng CZ, Albrecht T, (1991) Cellular oncogene activation by human cytomegalovirus. Lack of correlation with virus infectivity and immediate early gene expression. Arch Virol 118: 163-177.
28. Wang X, Huong SM, Chiu ML, Raab-Traub N, Huang ES, (2003) Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 424: 456-461.
29. Fausto N, (2000) Liver regeneration. J Hepatol 32: 19-31.
30. Joo M, Kang YK, Kim MR, Lee HK, Jang JJ, (2001) Cyclin D1 overexpression in hepatocellular carcinoma. Liver 21: 89-95.
31. Won C, Lee CS, Lee JK, Kim TJ, Lee KH, et al. (2010) CADPE suppresses cyclin D1 expression in hepatocellular carcinoma by blocking IL-6-induced STAT3 activation. Anticancer Res 30: 481-488.
32. Altieri DC, (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54.
33. Vogelstein B, Lane D, Levine AJ, (2000) Surfing the p53 network. Nature 408: 307-310.
34. Ji J, Wang XW, (2012) Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol 39: 461-472.
35. Cao L, Zhou Y, Zhai B, Liao J, Xu W, et al. (2011) Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterology 11: 71.
36. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, et al. (1999) Stat3 as an oncogene. Cell 98: 295-303.
37. Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, et al. (2009) Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457: 200-204.
38. Sun X, Zhang J, Wang L, Tian Z, (2008) Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 262: 201-213.
39. Gu FM, Li QL, Gao Q, Jiang JH, Zhu K, et al. (2011) IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer 10: 150.
40. Slinger E, Maussang D, Schreiber A, Siderius M, Rahbar A, et al. (2010) HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci Signal 3: ra58.
41. Bongers G, Maussang D, Muniz LR, Noriega VM, Fraile-Ramos A, et al. (2010) The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J Clin Invest 120: 3969-3978.
42. Tashiro E, Tsuchiya A, Imoto M, (2007) Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 98: 629-635.
43. Takahashi Y, Kawate S, Watanabe M, Fukushima J, Mori S, et al. (2007) Amplification of c-myc and cyclin D1 genes in primary and metastatic carcinomas of the liver. Pathol Int. Australia. pp. 437-442.
44. Driscoll B, Wu L, Buckley S, Hall FL, Anderson KD, et al. (1997) Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth. Am J Physiol 273: L941-949.
45. Peroukides S, Bravou V, Alexopoulos A, Varakis J, Kalofonos H, et al. (2010) Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin. Histol Histopathol 25: 299-307.
46. Botto S, Streblow DN, DeFilippis V, White L, Kreklywich CN, et al. (2011) IL-6 in human cytomegalovirus secretome promotes angiogenesis and survival of endothelial cells through the stimulation of survivin. Blood 117: 352-361.
47. Kruse JP, Gu W, (2009) Modes of p53 regulation. Cell 137: 609-622.
48. Kovacs A, Weber ML, Burns LJ, Jacob HS, Vercellotti GM, (1996) Cytoplasmic sequestration of p53 in cytomegalovirus-infected human endothelial cells. Am J Pathol 149: 1531-1539.
49. Muganda P, Mendoza O, Hernandez J, Qian Q, (1994) Human cytomegalovirus elevates levels of the cellular protein p53 in infected fibroblasts. J Virol 68: 8028-8034.
50. Speir E, Modali R, Huang ES, Leon MB, Shawl F, et al. (1994) Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265: 391-394.
51. Chen Z, Knutson E, Wang S, Martinez LA, Albrecht T, (2007) Stabilization of p53 in human cytomegalovirus-initiated cells is associated with sequestration of HDM2 and decreased p53 ubiquitination. J Biol Chem 282: 29284-29295.
52. Hsu CH, Chang MD, Tai KY, Yang YT, Wang PS, et al. (2004) HCMV IE2-mediated inhibition of HAT activity downregulates p53 function. Embo J 23: 2269-2280.
53. Abbas T, Dutta A, (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414.
54. Wagayama H, Shiraki K, Sugimoto K, Ito T, Fujikawa K, et al. (2002) High expression of p21WAF1/CIP1 is correlated with human hepatocellular carcinoma in patients with hepatitis C virus-associated chronic liver diseases. Hum Pathol 33: 429-434.
55. Shiraki K, Wagayama H, (2006) Cytoplasmic p21(WAF1/CIP1) expression in human hepatocellular carcinomas. Liver Int 26: 1018-1019.
56. Baccelli I, Trumpp A, (2012) The evolving concept of cancer and metastasis stem cells. J Cell Biol 198: 281-293.
57. Iliopoulos D, Hirsch HA, Wang G, Struhl K, (2011) Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA 108: 1397-1402.
58. Lin L, Fuchs J, Li C, Olson V, Bekaii-Saab T, et al. (2011) STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH+/CD133+ stem cell-like human colon cancer cells. Biochem Biophys Res Commun 416: 246-251.
59. Sherry MM, Reeves A, Wu JK, Cochran BH, (2009) STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 27: 2383-2392.
60. Michaelis M, Paulus C, Loschmann N, Dauth S, Stange E, et al. (2011) The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. Cell Mol Life Sci 68: 1079-1090.
61. Chen KF, Tai WT, Liu TH, Huang HP, Lin YC, et al. (2010) Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 16: 5189-5199.
62. Curtit E, Thiery-Vuillemin A, Nguyen T, Heyd B, Pivot X, et al. (2011) Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report. J Clin Oncol 29: e330-332.